Skip to main content
. 2017 Jan 4;8(7):11219–11227. doi: 10.18632/oncotarget.14494

Figure 1. SR-B1 expression with and without HDL NP treatment (healthy volunteers).

Figure 1

(A) Expression of SR-B1 and beta actin as measured by Western blot in PBMCs, B cells, and Ramos cells (positive control). (B) Expression of SR-B1 in PBMCs and B cells in the presence [10 nM (red), 30 nM (blue), or 100 nM (purple)] or absence [0 nM (orange)] of HDL NPs compared to isotype control (black).